EmitBio discovers novel treatment for COVID-19
Successful clinical trials demonstrate the power of our transformative treatment for people with mild-to-moderate COVID-19. This medical development directs precise wavelengths of safe, visible light to the oropharynx (back of throat) to shorten duration of illness. Subjects who used our treatment experienced:
- a 99.9% reduction of the mean SARS-CoV-2 viral load.
- a drop in viral load even after the light treatments stopped.
- faster resolution of COVID-19 symptoms—by more than 48 hours.
- and lower disease severity at all times during the treatment, when compared to the subject control group.
What’s an EmitBio light-based treatment like?
A rechargeable, handheld device* directs safe, non-UV light to the back of the throat during a five-minute treatment.
- The user sits in a comfortable position and tilts their head back
- The device signals a “3-2-1 countdown” prior to beginning
- A second treatment can be done 8 hours later
- The user repeats this for less than a week
*The EmitBio device is investigational and not currently available for sale.
How the EmitBio device works to treat COVID-19.
Unique treatment features:
Safe: Uses safe, visible spectrum light, not UV. This treatment has been shown in clinical trial with twice daily dosing to have no treatment related adverse effects and was also well tolerated in a separate study with healthy volunteers.
Five minutes, two times a day: A clinical trial showed that two quick treatments a day for less than a week were able to reduce viral load by up to 99.9% in people who had mild-to-moderate cases of COVID-19.
Treatment when you need it, in your own home: An easy-to-use, non-pharmacological treatment that can be used by an adult in an at-home setting. No daily visits to the doctor’s office or clinic.
Targeted treatment: The EmitBio device directs treatment that is directly bioavailable at a targeted area of need, the spot where the virus attempts to spread through the body. This can help avoid unwanted possible side effects of systemic treatments.
Mutation-agnostic: Unlike vaccines and monoclonal antibody treatments, the EmitBio treatment is not designed to be dependent on the genetics of specific SARS-CoV-2 strains or the configuration of spike protein on the virus. This potentially leads to utility as a treatment for current and future mutations.